Arlene Weintraub

Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.

Recent posts

Eleven Biotherapeutics Raises $20M to Advance Dry-Eye Drug

Cambridge, MA-based Eleven Biotherapeutics said today that it has expanded its Series A financing by $20 million, bringing the total raised in the funding round to $45 million. New investor JAFCO... Read more »
Retrophin, Headed by Controversial Hedge Fund Chief, Raises $4M

New York-based biotech company Retrophin announced this morning that it has completed a $4 million Series A round led by MSMB Capital, a life sciences hedge fund based in New York.... Read more »
NIH’s Collins Lauds “Unprecedented” Partnership at NY Bio Confab

Yesterday at the New York Biotechnology Association’s 21st annual meeting, National Institutes of Health director Francis Collins was beamed in by videoconference to a keynote lunch at the Times Square Marriott... Read more »
Pfizer Takes on Genzyme With New Gaucher Drug

Last night, just hours after New York drug giant Pfizer (NYSE: PFE) reported first-quarter profits that suffered from generic competition on its blockbuster cholesterol drug atorvastatin (Lipitor), the company announced... Read more »
Giffen Solutions, Created by Fed-Up Doc, Connects MDs and Patients

Michael Nusbaum rarely thought twice about giving his personal cell phone number to patients after he operated on them. Nusbaum is a bariatric surgeon at New Jersey’s Morristown Medical Center, and... Read more »
Mersana Adds $4M For Next-Generation “Armed” Cancer Drugs

Cambridge, MA-based Mersana Therapeutics is working in one of the hottest areas of biotech research—it’s figuring out new ways to attach potent anti-cancer drugs to specialized molecules that deliver the medicine... Read more »
New NYC Accelerator Boosts Health IT Startups

The New York eHealth Collaborative announced yesterday that it has created a new incubator, called the New York Digital Health Accelerator. The program, which is now accepting applications for its first... Read more »
Epizyme Gets $90M in Epigenetics Partnership with Celgene

Cambridge, MA-based Epizyme said today that it has formed a strategic partnership with an international subsidiary of Summit, NJ-based Celgene (NASDAQ: CELG). The two companies will work together to develop... Read more »
N-Gene Digs Up Funds to Boost “Heat Shock” Drug in Diabetes and MD

Drug development is never easy for cash-strapped biotechs, but for those wanting to make new drugs to treat diabetes—where the FDA demands clinical trials that are long and expensive—it can be... Read more »
New Data on Genzyme MS Drug Shows Improvement in Disability

One of the most closely watched developments in the quest for new multiple sclerosis treatments is the experimental drug alemtuzumab (Lemtrada) from Cambridge, MA-based Genzyme, a unit of French drug giant Sanofi... Read more »
Progress for Pervasis and InVivo: A Boost for Regenerative Efforts?

Last week brought good news for two Cambridge, MA companies pursuing different methods for repairing damaged body parts. Pervasis Therapeutics, which developed a cell-based method for fixing blood vessels, was acquired... Read more »
Pipeline Fellowship Grooms Female Angel Investors and Entrepreneurs

On March 30, Brittany Haas stepped before a firing line of 10 investors who were considering funding her New York-based startup, Happily Ever Borrowed, a website that rents veils, jewelry and... Read more »
Five Questions: Acorda CEO Ron Cohen on the Future of Neurology R&D

Hawthorne, NY-based Acorda Therapeutics (NASDAQ: ACOR) held its first R&D day for Wall Street analysts in six years today, and when CEO Ron Cohen was asked ‘why now?’ his answer was... Read more »
Enzyme Maker Alcresta Nabs $10M from Third Rock, Bessemer, Frazier

The team behind Newton, MA-based Allena Pharmaceuticals, which started up six months ago to develop enzyme-based drugs, is announcing today that they’ve formed a second enzyme company, Alcresta, to turn novel... Read more »
Provid Pharma Leans on MS Society’s Venture Fund to Boost Lead Drug

North Brunswick, NJ-based Provid Pharmaceuticals could be a case study in biotech bootstrapping. The company, founded in 2001, had been subsisting largely on angel funding, grants from the National Institutes of... Read more »
Core Innovation Capital’s $45M Fund Seeks Tech for the “Underbanked”

In 2007, a not-for-profit Chicago outfit called the Center for Financial Services Innovation launched a private equity fund to support tech startups with innovative financial products. The fund, says its New... Read more »
Merck Teams With Flagship to Bankroll Early Biotech Ventures

Cambridge, MA-based Flagship Ventures said today it has formed a partnership with Merck Research Ventures Fund—the $250 million fund the Whitehouse Station, NJ-based drug giant set up last year to... Read more »
See You Today at New England’s Emerging Biotech Stars***SOLD OUT***

We’re about to get going on this afternoon’s Xconomy Forum: New England’s Emerging Biotech Stars. But you still have a few hours to get your tickets. We have 8 left as... Read more »
OvaScience Adds $37M for Fertility Treatments

Boston-based OvaScience announced today that it has raised $37 million in a Series B financing, the proceeds of which it will pour into the development of infertility treatments based on stem... Read more »
Hard-Nosed Hedge Fund Chief Has Soft Spot for Rare-Disease Startup

On March 19, Martin Shkreli posted an article on the investing blog Seeking Alpha urging readers to “short” shares of San Diego-based Cytori (NASDAQ: CYTX)—essentially telling them they should bet... Read more »

Page 4 of 22 « previous page · next page »

Arlene Weintraub

Recent posts

Underwriters and Partners

Xconomy Events Across the Network

Connect with Xconomy

Xconomy’s Most Popular

Xconomy on Demand